BioSyent (CVE:RX) Stock Passes Above Fifty Day Moving Average – Here’s Why

BioSyent Inc. (CVE:RX)’s share price crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of C$11.14 and traded as high as C$11.21. BioSyent shares last traded at C$11.20, with a volume of 880 shares traded.

BioSyent Stock Performance

The firm’s 50-day moving average price is C$11.14 and its two-hundred day moving average price is C$11.04. The firm has a market capitalization of C$128.10 million, a PE ratio of 18.18 and a beta of 0.93. The company has a quick ratio of 6.91, a current ratio of 3.92 and a debt-to-equity ratio of 2.90.

Insider Buying and Selling at BioSyent

In other news, Senior Officer Robert Joseph March sold 4,775 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total value of C$55,628.75. Also, insider FAX Capital Corp. sold 112,400 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total value of C$1,267,557.28. Insiders have sold a total of 117,707 shares of company stock valued at $1,329,581 in the last 90 days. 33.65% of the stock is currently owned by corporate insiders.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.